Squamous Cell Carcinoma of the Head and Neck Cancer: PD 0332991 and Cetuximab in Patients
With Incurable SCCHN
What is the maximum tolerated dose of palbociclib when given in combination with cetuximab?
What are the effects of this drug combination and how effective is it?
Basic Study Information
Purpose:Location: Cancer Center
If you participate in this study you will be taking palbociclib and cetuximab as treatment
for your cancer. Palbociclib is taken by mouth once a day and cetuximab is given intravenously
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02101034?term=Phase+I%2FII+of+the+addition+of+Palbociclib+to+Cetuximab&rank=2https://clinicaltrials.gov/ct2/show/NCT02101034?term=Phase+I%2FII+of+the+addition+of+Palbociclib+to+Cetuximab&rank=2
Study Reference #: UHAN17040
Lead Researcher (Principal Investigator)
Lead Researcher: Ronald Maggiore
Study Contact InformationStudy Coordinator: Park Bogan
Phone: (585) 276-4415
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search